home / stock / vrca / vrca news

VRCA News and Press, Verrica Pharmaceuticals Inc. From 11/09/23

Stock Information
Company Name: Verrica Pharmaceuticals Inc.
Stock Symbol: VRCA
Market: NASDAQ
Website: verrica.com
Menu
VRCA VRCA Quote VRCA Short VRCA News VRCA Articles VRCA Message Board
Get VRCA Alerts

News, Short Squeeze, Breakout and More Instantly...
VRCA - Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Call Transcript

2023-11-09 09:57:02 ET Verrica Pharmaceuticals Inc. (VRCA) Q3 2023 Earnings Conference Call November 09, 2023 08:30 AM ET Company Participants Kevin Gardner - LifeSci Advisors Ted White - President & Chief Executive Officer\ Joe Bonaccorso - Chief Commercial ...
VRCA - Verrica Pharmaceuticals GAAP EPS of -$0.54 misses by $0.15, revenue of $2.92M beats by $2.45M

2023-11-09 07:36:56 ET More on Verrica Pharmaceuticals Seeking Alpha’s Quant Rating on Verrica Pharmaceuticals Historical earnings data for Verrica Pharmaceuticals Financial information for Verrica Pharmaceuticals For further details see: Verrica P...

VRCA - Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results

– Strong awareness and interest in prescribing YCANTH™ among dermatologists and pediatricians – – Over 112 million lives covered to date on commercial insurance and managed Medicaid plans – – Conference Call Scheduled for Today at 8:30...

VRCA - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
VRCA - Expected earnings - Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. (VRCA) is expected to report $-0.22 for Q3 2023

VRCA - Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023

WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host...

VRCA - Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH(TM) (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023

WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will hos...
VRCA - Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

WEST CHESTER, Pa., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that that Ted Whi...

VRCA - Verrica Pharmaceuticals Announces First Sale of YCANTH(TM) to FFF Enterprises

YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children FFF Enterprises is Verrica’s exclusive distribution partner for YCANTH&#x...

VRCA - Verrica Issues Statement in Support of FDA's Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum

Verrica’s product YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children YCANTH™ is expected to be available for commerci...
Previous 10 Next 10